Videos

The chief of hematology at Children’s Hospital of Philadelphia discussed the updated results she presented at ASH’s 2023 conference.

The medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed possible research to move forward with CD19 T-APCs for patients with B-ALL.

The professor of hematology at University of Lille and chair of LYSA also discussed what the group will be focusing on in 2024.

The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed the need for research into how CAR T-cells act differently between sexes.

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed new data from CLIMB-121 presented at ASH 2023 supporting Casgevy's approval.

The hematologist at the University of Navarra discussed updated data from the phase KarMMa-3 trial.

The chief medical officer of Orca Bio discussed some trends he was excited about at ASH’s 2023 conference.

The chief hematology/oncology fellow at University of Chicago discussed new data from the ROCCA collaborative study presented at ASH 2023.

The hematologist and cell therapist from the University of Miami Sylvester Comprehensive Cancer Center spoke about long-term outcome data he presented at ASH’s 2023 conference.

The chief medical officer of Orca Bio discussed data the company presented on its Orca-T and Orca-Q programs at ASH 2023.

The associate professor at Peter MacCallum Cancer Centre discussed case study research from the center and possible contributions to the case.

The professor of hematology at University of Lille and chair of LYSA shared updated data from the TRANSCEND-FL trial.

The bone marrow transplant physician at St. Jude Children’s Research Hospital also discussed the recent approval of exa-cel.

The medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed complete data from the PLAT-03 feasibility trial assessing SCRI-CAR19 and CD19t T-APCs in B-ALL.

The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed an analysis of female and male patient outcomes after axi-cel therapy.

The bone marrow transplant physician at St. Jude Children’s Research Hospital discussed an analysis of the sickle cell disease gene therapy he’s presenting on at ASH’s 2023 meeting.

The president and head of R&D at Taysha Gene Therapies discussed the early clinical evaluation of TSHA-102.

The associate professor of dermatology at Stanford University discussed his experiences investigating and helping to develop Vyjuvek, approved for treating DEB.

The director of cell therapy and transplant at Penn Medicine discussed the seminar he gave at the inaugural Cell Therapy for Autoimmune Disease Summit.

The assistant professor at MD Anderson Cancer Center discussed ongoing trials at MD Anderson and the TROP2 target for cell therapy.

The director of the Adult Sickle Cell Clinic and associate professor at University of Alabama Birmingham discussed the anticipated approval of the first gene therapy for SCD.

The professor in residence of pediatrics at University of California San Francisco discussed factors that will limit the potential first approval, including access and policy.

The associate professor of ophthalmology at Harvard Medical School discussed early results from a phase 1/2 trial from Mass Eye and Ear and partners.

The senior vice president and head of research at Kyverna Therapeutics discussed the company’s investigational CAR-T therapies, KYV-101 and KYV-201.

The Associate Professor of Medicine at Harvard Medical School discussed upcoming research and strategies to combat present hurdles in the treatment field.

The vice president of discovery at GentiBio discussed the panel she participated in at the inaugural Cell Therapy for Autoimmune Disease Summit.

The life science research professional at Stanford University discussed preclinical research she presented at the American Heart Association’s Scientific Sessions 2023.

The associate professor of clinical ophthalmology at University of Miami discussed potential future areas of investigation for gene therapy in ocular diseases.